MyFinsight
Home
Blog
About
EXPAREL
$147,823K
ZILRETTA
$32,648K
Iovera
$6,806K
Bupivacaine Liposome
Injectable Suspension
$3,216K
Product
$190,493K
(5.63%↑ Y/Y)
Royalty
$1,906K
(153.46%↑ Y/Y)
Total revenues
$192,399K
(6.24%↑ Y/Y)
Income from operations
$4,267K
(-49.79%↓ Y/Y)
Total operating
expenses
$188,132K
(9.00%↑ Y/Y)
Income (loss) before
income taxes
$2,555K
(232.59%↑ Y/Y)
Income tax benefit
(expense)
-$2,098K
(-171.85%↓ Y/Y)
Total other expense,
net
-$1,712K
(83.58%↑ Y/Y)
Interest income
$1,944K
(-61.18%↓ Y/Y)
Selling, general and
administrative
$91,809K
(3.65%↑ Y/Y)
Cost of goods sold
(exclusive of amortization...
$44,164K
(8.07%↑ Y/Y)
Research and development
$30,243K
(7.24%↑ Y/Y)
Amortization of acquired
intangible assets
$14,322K
(0.00%↑ Y/Y)
Other operating
expenses, net
-$7,594K
Net income (loss)
$4,653K
(196.00%↑ Y/Y)
Interest expense
$3,622K
(-22.85%↓ Y/Y)
Other, net
-$34K
(99.68%↑ Y/Y)
Back
Back
Income Statement
Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. (PCRX)
source: myfinsight.com